A Study to Assess NEU-111 in Healthy Participants

Phase 1 Completed 64 enrolled Neuron23 Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), multiple ascending dose (MAD), of orally administered NEU-111 in healthy subjects.

Timeline

Start: 2024-09-17
Primary completion: 2025-02-22
Completion: 2025-02-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NEU-111	Unknown	—	Oral

Indications

No indication recorded.